{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:25:17Z","timestamp":1756463117297,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s12094-020-02297-8","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T14:04:15Z","timestamp":1579701855000},"page":"1539-1547","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cyclooxygenase-2 expression as a prognostic factor in pediatric classical Hodgkin lymphoma"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5528-0025","authenticated-orcid":false,"given":"Y.","family":"Elborai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Elgammal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Salama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Fawzy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. D.","family":"El-Desouky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Attia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. M.","family":"Shalaby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,22]]},"reference":[{"key":"2297_CR1","unstructured":"Swerdlow SH, Campo E, Harris NL, et al. Hodgkin lymphoma In: World Health Organization, editor. Classification of tumors of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2008. p. 321-322"},{"issue":"4","key":"2297_CR2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"A Jemal","year":"2009","unstructured":"Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2009;59(4):225\u201349.","journal-title":"CA Cancer J Clin."},{"issue":"14","key":"2297_CR3","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1200\/JCO.2010.32.8401","volume":"29","author":"C Steidl","year":"2011","unstructured":"Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin\u2019s lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 2011;29(14):1812\u201326.","journal-title":"J Clin Oncol."},{"issue":"3","key":"2297_CR4","first-page":"e25","volume":"2","author":"M Barros","year":"2010","unstructured":"Barros M, Morais A, Morais V, et al. Prognostic factors in pediatric classic Hodgkin lymphoma: concept, questions and perspectives. J Pediatr Sci. 2010;2(3):e25.","journal-title":"J Pediatr Sci."},{"issue":"1","key":"2297_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/2045-3701-3-8","volume":"3","author":"V Allaj","year":"2013","unstructured":"Allaj V, Guo C, Nie D. Non-steroid anti-inflammatory drugs, prostaglandins, and cancer. Cell Biosci. 2013;3(1):8.","journal-title":"Cell Biosci."},{"issue":"5","key":"2297_CR6","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1248\/jhs.56.502","volume":"56","author":"A Divvela","year":"2010","unstructured":"Divvela A, Challa S, Tagaram I. Pathogenic role of cyclooxygenase-2 in cancer. J Health Sci. 2010;56(5):502\u201316.","journal-title":"J Health Sci."},{"issue":"1","key":"2297_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.arabjc.2011.07.020","volume":"6","author":"N Kumar","year":"2013","unstructured":"Kumar N, Drabu S, Mondal S. NSAID\u2019s and selectively COX-2 inhibitors as potential chemoprotective agents against cancer. Arab J Chem. 2013;6(1):1\u201323.","journal-title":"Arab J Chem."},{"issue":"10","key":"2297_CR8","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1002\/jcb.23226","volume":"112","author":"S Sung","year":"2011","unstructured":"Sung S, Park Y, Jo JR, et al. Overexpression of cyclooxygenase-2 in NCI-H292 human alveolar epithelial carcinoma cells: roles of p38 MAPK, ERK-1\/2, and PI3K\/PKB signaling proteins. J Cell Biochem. 2011;112(10):3015\u201324.","journal-title":"J Cell Biochem."},{"issue":"4","key":"2297_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.4111\/kju.2011.52.4.253","volume":"52","author":"BH Kim","year":"2011","unstructured":"Kim BH, Kim CI, Chang HS, et al. Cyclooxygenase-2 overexpression in chronic inflammation associated with benign prostatic hyperplasia: is it related to apoptosis and angiogenesis of prostate cancer? Korean J Urol. 2011;52(4):253\u20139.","journal-title":"Korean J Urol."},{"issue":"2","key":"2297_CR10","first-page":"429","volume":"7","author":"S Kulkarni","year":"2001","unstructured":"Kulkarni S, Rader JS, Zhang F, et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res. 2001;7(2):429\u201334.","journal-title":"Clin Cancer Res."},{"issue":"2","key":"2297_CR11","first-page":"171","volume":"32","author":"M Wang","year":"2011","unstructured":"Wang M, He Y, Shi L, et al. Multivariate analysis by cox proportional hazard model on prognosis of patient with epithelial ovarian cancer. Eur J Gynaecol Oncol. 2011;32(2):171\u20137.","journal-title":"Eur J Gynaecol Oncol."},{"issue":"4","key":"2297_CR12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.5808\/GI.2014.12.4.247","volume":"12","author":"JA Han","year":"2014","unstructured":"Han JA, Kim JY, Kim JI. Analysis of gene expression in cyclooxygenase-2-overexpressed human osteosarcoma cell lines. Genomics Inform. 2014;12(4):247\u201353.","journal-title":"Genomics Inform."},{"issue":"12","key":"2297_CR13","first-page":"4359","volume":"31","author":"F Hoellen","year":"2011","unstructured":"Hoellen F, Kelling K, Dittmer C, et al. Impact of cyclooxygenase-2 in breast cancer. Anticancer Res. 2011;31(12):4359\u201367.","journal-title":"Anticancer Res."},{"issue":"11","key":"2297_CR14","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","volume":"7","author":"TA Lister","year":"1989","unstructured":"Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin\u2019s disease: cotswolds meeting. J Clin Oncol. 1989;7(11):1630\u20136.","journal-title":"J Clin Oncol."},{"issue":"21","key":"2297_CR15","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","volume":"339","author":"D Hasenclever","year":"1998","unstructured":"Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin\u2019s disease: international prognostic factors project on advanced Hodgkin\u2019s disease. N Engl J Med. 1998;339(21):1506\u201314.","journal-title":"N Engl J Med."},{"issue":"4","key":"2297_CR16","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4):1244.","journal-title":"J Clin Oncol."},{"issue":"1","key":"2297_CR17","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s12105-017-0802-5","volume":"11","author":"NA Brown","year":"2017","unstructured":"Brown NA, Elenitoba-Johnson KS. Update from the 4th edition of the World Health Organization classification of head and neck tumours: hematolymphoid tumours. Head Neck Pathol. 2017;11(1):96\u2013109.","journal-title":"Head Neck Pathol."},{"issue":"12","key":"2297_CR18","first-page":"2765","volume":"6","author":"S Al-Salam","year":"2013","unstructured":"Al-Salam S, Awwad A, Sudhadevi M, et al. Epstein-Barr virus infection correlates with the expression of COX-2, p16INK4A and p53 in classic Hodgkin lymphoma. Int J Clin Exp Pathol. 2013;6(12):2765\u201377.","journal-title":"Int J Clin Exp Pathol."},{"issue":"9","key":"2297_CR19","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1080\/10428190600685442","volume":"47","author":"M Ohsawa","year":"2006","unstructured":"Ohsawa M, Fukushima H, Ikura Y, et al. Expression of cyclooxygenase-2 in Hodgkin\u2019s lymphoma: its role in cell proliferation and angiogenesis. Leuk Lymphoma. 2006;47(9):1863\u201371.","journal-title":"Leuk Lymphoma."},{"key":"2297_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1746-1596-5-19","volume":"5","author":"NO Barisik","year":"2010","unstructured":"Barisik NO, Bozkurt S, Gumus M, et al. Expression and prognostic significance of Cox-2 and p-53 in Hodgkin lymphomas: a retrospective study. Diagn Pathol. 2010;5:19.","journal-title":"Diagn Pathol."},{"issue":"25","key":"2297_CR21","doi-asserted-by":"publisher","first-page":"6072","DOI":"10.1182\/blood-2011-11-394627","volume":"119","author":"F Mestre","year":"2012","unstructured":"Mestre F, Gutierrez A, Ramos R, et al. Expression of COX-2 on Reed\u2013Sternberg cells is an independent unfavorable prognostic factor in Hodgkin lymphoma treated with ABVD. Blood. 2012;119(25):6072\u20139.","journal-title":"Blood"},{"issue":"8","key":"2297_CR22","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1097\/PAS.0b013e31828b6ad3","volume":"37","author":"YW Koh","year":"2013","unstructured":"Koh YW, Park C, Yoon DH, et al. Prognostic significance of COX-2 expression and correlation with Bcl-2 and VEGF expression, microvessel density, and clinical variables in classical Hodgkin lymphoma. Am J Surg Pathol. 2013;37(8):1242\u201351.","journal-title":"Am J Surg Pathol."},{"issue":"7","key":"2297_CR23","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1080\/10428190310001654032","volume":"45","author":"B Hazar","year":"2004","unstructured":"Hazar B, Ergin M, Seyrek E, et al. Cyclooxygenase-2 (Cox-2) expression in lymphomas. Leuk lymphoma. 2004;45(7):1395\u20139.","journal-title":"Leuk lymphoma."},{"issue":"1","key":"2297_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ijrobp.2014.10.004","volume":"92","author":"F Mestre","year":"2015","unstructured":"Mestre F, Guti\u00e9rrez A, Rodriguez J, et al. Radiation therapy overcomes adverse prognostic role of cyclooxygenase-2 expression on Reed\u2013Sternberg cells in early Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2015;92(1):84\u201390.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"12","key":"2297_CR25","doi-asserted-by":"publisher","first-page":"4784","DOI":"10.1182\/blood-2004-11-4201","volume":"105","author":"M Ladetto","year":"2005","unstructured":"Ladetto M, Vallet S, Trojan A, et al. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood. 2005;105(12):4784\u201391.","journal-title":"Blood"},{"issue":"9","key":"2297_CR26","first-page":"2118","volume":"53","author":"R Kurzrock","year":"1993","unstructured":"Kurzrock R, Redman J, Cabanillas F, et al. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin\u2019s disease and with B symptoms. Cancer Res. 1993;53(9):2118\u2013222.","journal-title":"Cancer Res."},{"issue":"14","key":"2297_CR27","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1200\/JCO.2003.07.127","volume":"21","author":"NK Altorki","year":"2003","unstructured":"Altorki NK, Keresztes RS, Port JL, et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol. 2003;21(14):2645\u201350.","journal-title":"J Clin Oncol."},{"issue":"11","key":"2297_CR28","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1038\/bjc.2011.443","volume":"105","author":"ET Chang","year":"2011","unstructured":"Chang ET, Fr\u00f8slev T, S\u00f8rensen HT, et al. Nationwide study of aspirin other non-steroidal anti-inflammatory drugs and Hodgkin lymphoma risk in Denmark. Br J Cancer. 2011;105(11):1776\u2013822.","journal-title":"Br J Cancer."}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-020-02297-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-020-02297-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-020-02297-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:20:46Z","timestamp":1611188446000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-020-02297-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,22]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["2297"],"URL":"https:\/\/doi.org\/10.1007\/s12094-020-02297-8","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"type":"print","value":"1699-048X"},{"type":"electronic","value":"1699-3055"}],"subject":[],"published":{"date-parts":[[2020,1,22]]},"assertion":[{"value":"28 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The IRB approved Dr. Ahmed Hussein Al Gammal to conduct this study at the National Cancer Institute - Cairo University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}